(Reuters) -Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

surpassing the Medical sector's loss of 6.22% and falling behind the S&P 500's loss of 1.7%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure.

It holds 37 stocks in its basket, with Eli Lilly taking the top spot at 16.3% of the portfolio. Horizon Kinetics Medical ETF has gathered $15.6 million in its asset base and charges 85 bps in ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.